TYPHOID AND PARATYPHOID A AND B: THE RELEVANCE OF IMPROVING MEASURES FOR THEIR DETECTION AND TREATMENT
- Authors
-
-
Karima Abdurakhmonova
Assistant of the Department of Microbiology Virusology and Immunology of Tashkent State Medical University, Tashkent, Uzbekistan
Author
-
Ulug'bek Malikjonov
Student of the 2nd Faculty of General Medicine of Tashkent State Medical University, Tashkent, Uzbekistan
Author
-
Javokhir Komilov
Student of the 2nd Faculty of General Medicine of Tashkent State Medical University, Tashkent, Uzbekistan
Author
-
Shokhidbek Odilov
Student of the 2nd Faculty of General Medicine of Tashkent State Medical University, Tashkent, Uzbekistan
Author
-
- Keywords:
- Array
- Abstract
-
Salmonella enterica serovars Typhi and Paratyphi (S. Typhi and S. Paratyphi) are the cause of enteric fever, a potentially fatal systemic febrile illness. Regretfully, despite ongoing progress in the field, the disease's burden is still significant, mostly because of the worldwide proliferation of different drug-resistant strains of Salmonella. For the condition to be effectively controlled, a precise diagnosis is essential. Feverish bacterial diseases like typhoid and paratyphoid (enteric fever) are prevalent in many low- and middle-income nations. Due to widespread resistance to earlier, first-line antibiotics, the World Health Organization (WHO) currently advises therapy with azithromycin, ciprofloxacin, or ceftriaxone. Resistance patterns change over time and differ depending on the region. Ciprofloxacin is frequently ineffective in South Asia due to fluoroquinolone resistance. In Pakistan, enteric fever strains that are highly resistant to drugs have surfaced. Susceptibility to outdated first-line antibiotics, such chloramphenicol, has resurfaced in some parts of the world. The use of azithromycin and fluoroquinolones in the treatment of enteric fever has previously been the subject of a Cochrane Review; however, the use of cephalosporins has not been well examined, and the best course of action and length of treatment are unknown. The potentially serious and sometimes fatal bacteremic illnesses caused by Salmonella enterica serotypes Typhi, Paratyphi A, Paratyphi B (tartrate negative), and Paratyphi C are known as typhoid fever (for the Typhi serotype), paratyphoid fever (for the Paratyphi serotypes), and enteric fever. There are currently no diagnostic techniques for identifying asymptomatic carriers, and laboratory assays exhibit subpar sensitivity and specificity. To find more precise biomarkers for early detection and asymptomatic carrier detection, a number of research initiatives have used systemic techniques. The advantages and disadvantages of the enteric fever diagnostic tests that are now on the market, the progress of research toward better diagnostic tests, and the difficulties in finding new, optimal biomarkers and tests are all covered in this review.
- References
-
1.Kuehn R, Stoesser N, Eyre D, Darton TC, Basnyat B, Parry CM. Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins. Cochrane Database Syst Rev. 2022 Nov 24;11(11):CD010452. doi: 10.1002/14651858.CD010452.pub2.
2.Francois Watkins LK, Shih DC, Dorough L. Typhoid and Paratyphoid Fever. 2025 Apr 23. In: Halsey ES, Angelo KM, Barnett ED, et al., editors. CDC Yellow Book, 2026 edition: Health Information for International Travel [Internet]. Atlanta (GA): Centers for Disease Control and Prevention (US); 2025 Apr 23. Available from: https://www.ncbi.nlm.nih.gov/books/NBK620886/
3.Syed, K. A., Saluja, T., Cho, H., Hsiao, A., Shaikh, H., Wartel, T. A., Mogasale, V., Lynch, J., Kim, J. H., Excler, J. L., & Sahastrabuddhe, S. (2020). Review on the Recent Advances on Typhoid Vaccine Development and Challenges Ahead. Clinical Infectious Diseases, 71(Suppl 2), S141–S150. 10.1093/cid/ciaa504
4.Neupane DP, Dulal HP, Song J. Enteric Fever Diagnosis: Current Challenges and Future Directions. Pathogens. 2021 Apr 1;10(4):410. doi: 10.3390/pathogens10040410.
5.Stanaway JD, Reiner RC, Blacker BF, Goldberg EM, Khalil IA, Troeger CE, et al. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infectious Diseases 2019;19(4):369-81.
6.World Health Organization. Model List of Essential Medicines - 22nd List, 2021. WHO/MHP/HPS/EML/2021.02. who.int/publications/i/item/WHO-MHP-HPS-EML-2021.02.
7.World Health Organization. Typhoid vaccines: WHO position paper, March 2018 – Recommendations. World Health Organization 2019;37(2):214-6. [DOI: 10.1016/j.vaccine.2018.04.022]
8.Crump J. A. (2019). Progress in Typhoid Fever Epidemiology. Clinical Infectious Diseases, 68(Suppl 1), S4–S9. 10.1093/cid/ciy846
9.Shakya M, Voysey M, Theiss-Nyland K, Colin-Jones R, Pant D, Adhikari A, et al. Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial. Lancet Global Health 2021;9(11):e1561
10.Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Available from training.cochrane.org/handbook.
11.Qadri F, Khanam F, Liu X, Theiss-Nyland K, Biswas PK, Bhuiyan AI, et al. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. Lancet 2021;398(10301):01124-7. [DOI: 10.1016/S0140-6736]
12.McAteer, J., Derado, G., Hughes, M., Bhatnagar, A., Medalla, F., Chatham-Stevens, K., Appiah, G. D., & Mintz, E. (2021). Typhoid Fever in the U.S. Pediatric Population, 1999-2015: Opportunities for Improvement. Clinical Infectious Diseases, 73(11), e4581–e4589. 10.1093/cid/ciaa914
13.Qureshi S, Naveed AB, Yousafzai MT, Ahmad K, Ansari S, Lohana H, et al. Response of extensively drug resistant Salmonella typhi to treatment with meropenem and azithromycin, in Pakistan. PLOS Neglected Tropical Diseases 2020;14(10):e0008682.
14.Patel PD, Patel P, Liang Y, Meiring JE, Misiri T, Mwakiseghile F, et al. Safety and efficacy of a typhoid conjugate vaccine in Malawian children. New England Journal of Medicine 2021;385(12):1104-15. [DOI: 10.1056/NEJMoa2035916]
15.Institute for Health Metrics and Evaluation. GBD results from the Global Burden of Disease study. Healthdata.org. https://vizhub.healthdata.org/gbd-results/. Accessed on September 1, 2023.Neupane DP, Dulal HP, Song J. Enteric fever diagnosis: current challenges and future directions. Pathogens 2021;10(4):410.
16.Nabarro LE, McCann N, Herdman MT, Dugan C, Ladhani S, Patel D, et al. British infection association guidelines for the diagnosis and management of enteric fever in England. Journal of Infection 2022;84(4):469-89. [DOI: 10.1016/j.jinf.2022.01.014]
17.Meiring JE, Shakya M, Khanam F, Voysey M, Phillips MT, Tonks S, et al. Burden of enteric fever at three urban sites in Africa and Asia: a multicentre population-based study. Lancet Global Health 2021;9(12):e1688-96. [DOI: 10.1016/S2214-109X(21)00370-3]
18.Iqbal J, Dehraj IF, Carey ME, Dyson ZA, Garrett D, Seidman JC, et al. A race against time: reduced azithromycin susceptibility in Salmonella enterica serovar typhi in Pakistan. Msphere 2020;5(4):e00215-20.
19.Hooda Y, Sajib MS, Rahman H, Luby SP, Bondy-Denomy J, Santosham M, et al. Molecular mechanism of azithromycin resistance among typhoidal Salmonella strains in Bangladesh identified through passive pediatric surveillance. PLOS Neglected Tropical Diseases 2019;13(11):e0007868.
20.Garrett DO, Longley AT, Aiemjoy K, Yousafzai MT, Hemlock C, Alexander TY, et al. Incidence of typhoid and paratyphoid fever in Bangladesh, Nepal, and Pakistan: results of the Surveillance for Enteric Fever in Asia Project. Lancet Global Health 2022;10(7):e978-88. [DOI: 10.1016/S2214-109X(22)00119-X]
21.Browne, A. J., Kashef Hamadani, B. H., Kumaran, E. A. P., Rao, P., Longbottom, J., Harriss, E., Moore, C. E., Dunachie, S., Basnyat, B., Baker, S., Lopez, A. D., Day, N. P. J., Hay, S. I., & Dolecek, C. (2020). Drug-resistant enteric fever worldwide, 1990 to 2018: a systematic review and meta-analysis. BMC Medicine, 18(1), 1. 10.1186/s12916-019-1443-1
22.Fowler C.C., Chang S.J., Gao X., Geiger T., Stack G., Galán J.E. Emerging insights into the biology of typhoid toxin. Curr. Opin. Microbiol. 2017;35:70–77. doi: 10.1016/j.mib.2017.01.012.
23.Helman S.K., Mummah R.O., Gostic K.M., Buhnerkempe M.G., Prager K.C., Lloyd-Smith J.O. Estimating prevalence and test accuracy in disease ecology: How Bayesian latent class analysis can boost or bias imperfect test results. Ecol. Evol. 2020;10:7221–7232. doi: 10.1002/ece3.6448.
24.Andrews J.R., Khanam F., Rahman N., Hossain M., Bogoch I.I., Vaidya K., Kelly M., Calderwood S.B., Bhuiyan T.R., Ryan E.T., et al. Plasma Immunoglobulin A Responses Against 2 Salmonella Typhi Antigens Identify Patients with Typhoid Fever. Clin. Infect. Dis. 2019;68:949–955. doi: 10.1093/cid/ciy578.
25.Kumar S., Nodoushani A., Khanam F., DeCruz A.T., Lambotte P., Scott R., Bogoch I.I., Vaidya K., Calderwood S.B., Bhuiyan T.R., et al. Evaluation of a Rapid Point-of-Care Multiplex Immunochromatographic Assay for the Diagnosis of Enteric Fever. mSphere. 2020;5 doi: 10.1128/mSphere.00253-20.
- Downloads
- Published
- 2026-05-05
- Section
- Articles